13 May 2024
13 May 2024
19 May 2023
11 May 2023
05 June 2023
19 May 2023
![](https://www.ipsen.com/us/wp-content/themes/ipsen-main/dist/images/radio-icon.png)
-
30 June 2023
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
PARIS, FRANCE, 30 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigat...